This mechanism was verified with multiple lung and breast cancer cell lines, and the study demonstrated that in FRA1-driven cancer cells, PARP7 expression alone is necessary and sufficient to predict PARP7 inhibitor sensitivity. This evidence concerns the gene FOSL1 and breast carcinoma.